SIL1 and Marinesco-Sjogren syndrome: The logistical challenges for the discovery of new treatment options for MSS are similar to those for any rare disease, but the large number of distinct MSS-associated SIL1 mutations, coupled with the variety of tissues affected and an incomplete understanding of the pathomechanisms of all primary defects, all hinder the exploration of potential therapeutic strategies for MSS.